Arrowhead Research | ARWR - Interest Expense On Debt


Arrowhead Research reported $24.56M in Interest Expense on Debt for its fiscal quarter ending in June of 2026.





Interest Expense On Debt Change Date
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
Anika Therapeutics 183.47M 4.09M Jun/2026
Arrowhead Research USD 24.56M 716K Jun/2026
Heron Therapeutics USD 600K 100K Dec/2024
Incyte USD 582K 13K Jun/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
Merck USD 525M 46M Jun/2026
Moderna USD 10.96B 527M Jun/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Novartis USD 462M 119M Jun/2026
Sarepta Therapeutics USD 21.51M 205K Jun/2026
TG Therapeutics USD 16.57M 8.91M Jun/2026
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Xencor USD 7.35M 2.65M Jun/2026